liver

Primary-Stage Colon Cancer Impairs Muscle Energy Metabolism by Suppressing Mitochondrial Complex I Activity.

<p><b>BACKGROUND</b></p><p>Colon cancer (CC), the third most common cancer worldwide, is accompanied by cachexia in 30% of patients. Its associated muscle loss directly impairs therapeutic response and survival. Early intervention is crucial, yet the underlying mechanisms of early-stage muscle dysfunction remain...

๐Ÿ—“๏ธ 2025-11-12
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MorePrimary-Stage Colon Cancer Impairs Muscle Energy Metabolism by Suppressing Mitochondrial Complex I Activity.

Sarcopenia and MASLD: novel insights and the future.

Metabolic dysfunction-associated steatotic liver disease (MASLD; previously known as non-alcoholic fatty liver disease) is the leading cause of chronic liver disease worldwide and is closely linked to the obesity epidemic. MASLD often coexists with sarcopenia, an age-related loss of muscle...

๐Ÿ—“๏ธ 2025-11-06
๐Ÿ“ฐ Publication: Nature Reviews Endocrinology
Read MoreSarcopenia and MASLD: novel insights and the future.

Effect of Skeletal Muscle Mass and Its Associated Mediators on the Development of Steatotic Liver Disease: A Cohort Study in China.

<p><b>BACKGROUND</b></p><p>Understanding the relationship between relative skeletal muscle mass and newly proposed steatotic liver disease (SLD) is crucial, but research gaps still exist. Based on a cohort study, we investigated the impact of relative skeletal muscle mass on incident SLD and...

๐Ÿ—“๏ธ 2025-11-04
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreEffect of Skeletal Muscle Mass and Its Associated Mediators on the Development of Steatotic Liver Disease: A Cohort Study in China.

Overt hepatic encephalopathy after elective and preemptive TIPS: Risk factors and prognosis.

<p><b>BACKGROUND & AIMS</b></p><p>Overt hepatic encephalopathy (OHE) develops in 30-50% of patients after transjugular intrahepatic portosystemic shunt (TIPS) placement, depending on patient characteristics and TIPS indication. Data on OHE after preemptive TIPS (pTIPS) are limited. We aimed to assess the prevalence...

๐Ÿ—“๏ธ 2025-10-29
๐Ÿ“ฐ Publication: Jhep Reports
Read MoreOvert hepatic encephalopathy after elective and preemptive TIPS: Risk factors and prognosis.

Sarcopenia and gender disparities in liver transplant waiting lists: evaluating predictive scores and delisting risks.

<p><b>BACKGROUND</b></p><p>The model for end-stage liver disease (MELD) and model for end-stage liver disease-sodium (MELD-Na) scores are the most widely used for prioritizing patients on the liver transplant (LT) waiting list. However, the quality and accuracy of these scores are questionable....

๐Ÿ—“๏ธ 2025-10-01
๐Ÿ“ฐ Publication: Hepatobiliary Surgery And Nutrition
Read MoreSarcopenia and gender disparities in liver transplant waiting lists: evaluating predictive scores and delisting risks.

Association of Hormonal Status With Sarcopenia, Frailty and Outcome in Patients With Decompensated Cirrhosis.

<p><b>BACKGROUND AND AIMS</b></p><p>Sarcopenia and frailty have been associated with hormonal dysregulation in non-cirrhotic populations. The aim of the study was to evaluate hypothalamic-pituitary-adrenal and gonadal (HPA-HPG) axes as well as growth hormone/insulin-like growth factor-1 (GH/IGF-1) levels in patients with cirrhosis...

๐Ÿ—“๏ธ 2025-11-01
๐Ÿ“ฐ Publication: Liver International
Read MoreAssociation of Hormonal Status With Sarcopenia, Frailty and Outcome in Patients With Decompensated Cirrhosis.

Management of Children Awaiting Liver Transplantation: Sarcopenia, Cholestasis and Beyond.

Sarcopenia has been increasingly recognized as a risk factor for worse outcomes in liver transplantation; however, the data remain limited on pediatric-specific outcomes. These gaps in knowledge are in part due to the lack of a standardized definition, challenges inherent...

๐Ÿ—“๏ธ 2025-11-01
๐Ÿ“ฐ Publication: Pediatric Transplantation
Read MoreManagement of Children Awaiting Liver Transplantation: Sarcopenia, Cholestasis and Beyond.

Silencing Myostatin Using In Vivo Self-Assembled siRNA Protects Against Cancer- and Dexamethasone-Induced Muscle Atrophy.

Maintaining skeletal muscle mass is crucial for health, as muscle atrophy caused by drugs, cancer, or aging poses serious risks. However, there are few effective pharmacological interventions targeting muscle atrophy, highlighting the need for new therapeutic strategies. In this study,...

๐Ÿ—“๏ธ 2025-10-03
๐Ÿ“ฐ Publication: Advanced Healthcare Materials
Read MoreSilencing Myostatin Using In Vivo Self-Assembled siRNA Protects Against Cancer- and Dexamethasone-Induced Muscle Atrophy.

Type II fibre atrophy and nuclear disruption in decompensated cirrhosis.

Loss of skeletal muscle mass is a common complication in cirrhosis that is associated with higher morbidity and mortality. Since the specific pathophysiology of cirrhosis-related muscle loss is unclear, we performed histological evaluation of muscle tissue from patients with cirrhosis...

๐Ÿ—“๏ธ 2025-05-24
๐Ÿ“ฐ Publication: Jhep Reports
Read MoreType II fibre atrophy and nuclear disruption in decompensated cirrhosis.

Vagal blockade of the brain-liver axis deters cancer-associated cachexia.

Cancer-associated cachexia (CAC) is a multifactorial and currently incurable syndrome responsible for nearly one-third of cancer-related deaths. It contributes to therapy resistance and increases mortality among affected patients. In this study, we show that cancer-induced systemic inflammation alters vagal tone...

๐Ÿ—“๏ธ 2025-07-29
๐Ÿ“ฐ Publication: Cell
Read MoreVagal blockade of the brain-liver axis deters cancer-associated cachexia.

Cancer therapy and cachexia.

A central challenge in cancer therapy is the effective delivery of anticancer treatments while minimizing adverse effects on patient health. The potential dual impact of therapy is clearly illustrated in cancer-associated cachexia, a multifactorial syndrome characterized by involuntary weight loss,...

๐Ÿ—“๏ธ 2025-08-01
๐Ÿ“ฐ Publication: Journal Of Clinical Investigation
Read MoreCancer therapy and cachexia.

Functional liver genomics identifies hepatokines promoting wasting in cancer cachexia.

In cancer cachexia, the presence of a tumor triggers systemic metabolic disruption that leads to involuntary body weight loss and accelerated mortality in affected patients. Here, we conducted transcriptomic and epigenomic profiling of the liver in various weight-stable cancer and...

๐Ÿ—“๏ธ 2025-07-18
๐Ÿ“ฐ Publication: Cell
Read MoreFunctional liver genomics identifies hepatokines promoting wasting in cancer cachexia.

Impact of physical activities in metabolic dysfunction associated steatotic liver disease, sarcopenia, and cardiovascular disease.

There are no comprehensive studies that investigated differential effects of physical activity (PA) types on metabolic dysfunction associated steatotic liver disease (MASLD) and their associations with sarcopenia and cardiovascular disease. A cross-sectional analysis using data from 66,021 participants from the...

๐Ÿ—“๏ธ 2025-04-28
๐Ÿ“ฐ Publication: Diabetes Research And Clinical Practice
Read MoreImpact of physical activities in metabolic dysfunction associated steatotic liver disease, sarcopenia, and cardiovascular disease.

Integrated Multiomics Analyses of the Molecular Landscape of Sarcopenia in Alcohol-Related Liver Disease.

Skeletal muscle is a major target for ethanol-induced perturbations, leading to sarcopenia in alcohol-related liver disease (ALD). The complex interactions and pathways involved in adaptive and maladaptive responses to ethanol in skeletal muscle are not well understood. Unlike hypothesis-driven experiments,...

๐Ÿ—“๏ธ 2025-06-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreIntegrated Multiomics Analyses of the Molecular Landscape of Sarcopenia in Alcohol-Related Liver Disease.

Severe Dietary Energy Restriction for Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomised Controlled Trial.

Compensated cirrhosis due to metabolic dysfunction-associated steatotic liver disease (CC-MASLD) increases morbidity and mortality risk but has no aetiology-specific treatment. We investigated the safety and efficacy signals of severe energy restriction. In this randomised controlled trial, adults with CC-MASLD and...

๐Ÿ—“๏ธ 2025-06-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreSevere Dietary Energy Restriction for Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomised Controlled Trial.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!